Safety and Efficacy of the Epithelial Sodium Channel Blocker Idrevloride in People With Primary Ciliary Dyskinesia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial
Lancet Respir Med 2023 Aug 31;[EPub Ahead of Print], FC Ringshausen, AJ Shapiro, KG Nielsen, H Mazurek, M Pifferi, KH Donn, MM van der Eerden, MR Loebinger, MA Zariwala, MW Leigh, MR Knowles, TW FerkolFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.